

SPAK (STK39) Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP1448b**Specification**

SPAK (STK39) Antibody (C-term) Blocking peptide - Product InformationPrimary Accession [Q9UEW8](#)**SPAK (STK39) Antibody (C-term) Blocking peptide - Additional Information**

Gene ID 27347

Other Names

STE20/SPS1-related proline-alanine-rich protein kinase, Ste-20-related kinase, DCHT, Serine/threonine-protein kinase 39, STK39, SPAK

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP1448b](/product/products/AP1448b) was selected from the C-term region of human STK39. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SPAK (STK39) Antibody (C-term) Blocking peptide - Protein Information

Name STK39

Function

Effector serine/threonine-protein kinase component of the WNK-SPAK/OSR1 kinase cascade, which is involved in various processes, such as ion transport, response to hypertonic stress and blood pressure (PubMed: [16669787](http://www.uniprot.org/citations/16669787), PubMed: [18270262](http://www.uniprot.org/citations/18270262), PubMed: [21321328](http://www.uniprot.org/citations/21321328), PubMed: [34289367](http://www.uniprot.org/citations/34289367)). Specifically recognizes and binds proteins with a RFXV motif (PubMed: [16669787](http://www.uniprot.org/citations/16669787), PubMed: [21321328](http://www.uniprot.org/citations/21321328)). Acts downstream of WNK kinases (WNK1, WNK2, WNK3 or WNK4): following activation by WNK kinases, catalyzes phosphorylation of ion cotransporters, such as SLC12A1/NKCC2,

SLC12A2/NKCC1, SLC12A3/NCC, SLC12A5/KCC2 or SLC12A6/KCC3, regulating their activity (PubMed:21321328). Mediates regulatory volume increase in response to hyperosmotic stress by catalyzing phosphorylation of ion cotransporters SLC12A1/NKCC2, SLC12A2/NKCC1 and SLC12A6/KCC3 downstream of WNK1 and WNK3 kinases (PubMed:12740379, PubMed:16669787, PubMed:21321328). Phosphorylation of Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their activation and ion influx; simultaneously, phosphorylation of K-Cl cotransporters SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, blocking ion efflux (PubMed:16669787, PubMed:19665974, PubMed:21321328). Acts as a regulator of NaCl reabsorption in the distal nephron by mediating phosphorylation and activation of the thiazide-sensitive Na-Cl cotransporter SLC12A3/NCC in distal convoluted tubule cells of kidney downstream of WNK4 (PubMed:18270262). Mediates the inhibition of SLC4A4, SLC26A6 as well as CFTR activities (By similarity). Phosphorylates RELT (By similarity).

Cellular Location

Cytoplasm. Nucleus. Note=Nucleus when caspase-cleaved.

Tissue Location

Predominantly expressed in brain and pancreas followed by heart, lung, kidney, skeletal muscle, liver, placenta and testis.

SPAK (STK39) Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

SPAK (STK39) Antibody (C-term) Blocking peptide - Images**SPAK (STK39) Antibody (C-term) Blocking peptide - Background**

STK39 is a serine/threonine kinase that is thought to function in the cellular stress response pathway. The kinase is activated in response to hypotonic stress, leading to phosphorylation of several cation-chloride-coupled cotransporters. The catalytically active kinase specifically activates the p38 MAP kinase pathway, and its interaction with p38 decreases upon cellular stress, suggesting that this kinase may serve as an intermediate in the response to cellular stress.

SPAK (STK39) Antibody (C-term) Blocking peptide - References

Dowd, B.F., et al., J. Biol. Chem. 278(30):27347-27353 (2003). Johnston, A.M., et al., Oncogene 19(37):4290-4297 (2000).